If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

Funding Update

13 Nov 2023 08:42

RNS Number : 2380T
Microsaic Systems plc
13 November 2023
 

13 November 2023

Microsaic Systems plc

("Microsaic" or the "Company")

Funding update

 

The Company announced on 3 November that it had begun a very significant cost reduction exercise which would include a substantially reduced operation cost base and the intention to reduce overheads by cancelling admission to trading of its shares on AIM ("Delisting") and conversion to a private company.

The Company has since been engaged in further funding discussions which involve raising funds subject to reinstatement of the Company's shares to trading on AIM. The Company is reviewing the proposals and will provide a further update on the resolutions to be put to shareholders to give effect to such proposals as soon as is reasonably practicable, along with an updated timetable for key events. This will include the revised timing for publication and posting of a circular to shareholders giving notice of a general meeting. The Directors believe that concluding a modest fundraise to support the retention of the AIM listing would be in the best interests of the Company in the medium term. Completion of such a fundraising remains conditional upon, inter alia, the publication of both the FY22 audited annual accounts on a going concern basis and the interim results for the six months ended 30 June 2023.

It is likely that, if proceeding with a fundraising subject to obtaining fresh shareholder authorities to allot new shares on a non-pre-emptive basis, the Company would still need to table an alternate resolution to approve Delisting in the event that the resolutions required to implement a fundraising were not passed. If the fundraising resolutions were to be approved, with firm commitments obtained from investors prior to the GM then being subject only to admission of the new shares (i.e. assuming reinstatement will occur), the Delisting resolution would be withdrawn from the business of the General Meeting.

 

Enquiries:

Microsaic Systems plc

Bob MooreExecutive Chairman

+44 (0)1483 751 577

Singer Capital Markets(Nominated Adviser & Joint Broker)

+44 (0)20 7496 3000

Aubrey Powell / Angus Campbell

 

 

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

 

 

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information as stipulated under the UK version of the market abuse regulation no 596/2014 which is part of English law by virtue of the European Union (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain. The above named director takes responsibility for the release of this announcement.

 

About Microsaic (www.microsaic.com)

Microsaic listed on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested £30m over the last 20 years before and after the IPO, Microsaic has a robust patent portfolio in cutting-edge technology which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow.

 

Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing, and point-of-need applications. Microsaic is an innovative company. Most recently the Company has developed an Acrylamide detector for use in the food industry and a ProteinID detector for the biopharma industry that will greatly reduce the manufacturing wastage costs by early detection of expensive product failure throughout the biopharmaceutical manufacturing process. For environmental monitoring, Microsaic has developed a method to analyse perfluoroalkyl-and polyfluoroalkyl (PFAS) substances, otherwise known as 'forever chemicals' using its mass spectrometer. This equipment can analyse water samples and determine whether PFAS concentrations are above legal thresholds with novel mobile testing capability. All of these new products are at the final stage of development and are expected to be released to the market in 2024.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUOOWROKUAARA
Date   Source Headline
28th Oct 20149:16 amRNSHolding(s) in Company
14th Oct 20142:10 pmRNSHolding(s) in Company
10th Oct 20144:19 pmRNSHolding(s) in Company
10th Oct 20141:15 pmRNSExercise of Share Options
8th Oct 20147:00 amRNSDirectors' Dealings
7th Oct 20147:00 amRNSConditional Placing to Raise £4.4 million
30th Sep 20147:00 amRNSInterim Results
29th Sep 201412:23 pmRNSCommercial Agreement with Gilson Inc.
25th Sep 20147:00 amRNSMicrosaic Systems Signs Commercial Agreement
9th Sep 20147:00 amRNSPlexus chosen as commercial manufacturing partner
15th Jul 201410:06 amRNSDirectorate Change
23rd Jun 20143:08 pmRNSHolding(s) in Company
19th Jun 201412:02 pmRNSHolding(s) in Company
13th Jun 20149:00 amRNSDISTRIBUTION OF ANNUAL REPORT & ACCOUNTS
10th Jun 20149:10 amRNSExercise of share options
3rd Jun 20147:00 amRNSResult of AGM
30th May 20141:09 pmRNSNotification of Major Interest in Shares
6th May 201411:58 amRNSGRANT OF SHARE OPTIONS
30th Apr 20147:00 amRNSPreliminary Results
28th Apr 201412:33 pmRNSNotification of Major Interest in Shares
23rd Apr 20148:18 amRNSNotification of Major Interest in Shares
17th Apr 20149:19 amRNSHolding(s) in Company
15th Apr 20149:17 amRNSAppointment of Finance Director
14th Apr 20149:42 amRNSRe Agreement
11th Dec 20133:56 pmRNSHolding(s) in Company
21st Oct 20137:00 amRNSFormation of new Scientific Advisory Group
27th Sep 20137:00 amRNSInterim Results
1st Jul 20137:00 amRNSAppointment of Chairman
24th Jun 20137:00 amRNSIssue of Equity
4th Jun 20135:08 pmRNSHolding(s) in Company
4th Jun 20137:00 amRNSMicrosaic welcomes launch of the IsoleraT Dalton
31st May 201310:28 amRNSHolding(s) in Company
28th May 20132:44 pmRNSHolding(s) in Company
24th May 201311:23 amRNSResults of General Meeting
15th May 201311:23 amRNSResults of Annual General Meeting
7th May 20134:35 pmRNSDistribution of Circular of General Meeting
3rd May 20136:25 pmRNSConditional Placing to Raise up to £4.28 million
22nd Apr 20137:00 amRNSDistribution of Annual Report and Accounts
15th Apr 20137:00 amRNSPreliminary Results
10th Apr 20137:00 amRNSSigning of commercial agreement
15th Mar 20131:05 pmRNSHolding(s) in Company
14th Mar 20139:00 amRNSLaunch New Chip-based Mass Spectrometry Instrument
12th Dec 20129:36 amRNSGrant of Share Options
19th Oct 20124:45 pmRNSDirector/PDMR Shareholding
15th Oct 20122:26 pmRNSDirector/PDMR Shareholding
24th Sep 20127:00 amRNSAppointment of new CEO
24th Sep 20127:00 amRNSInterim Results
4th Sep 201210:00 amRNSAgreement
4th Jul 20129:46 amRNSGrant of Share Options
25th Jun 201210:29 amRNSMicrosaic Wins R&D100 Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.